ADC Therapeutics SA Common Shares (ADCT)
ADCT trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/0001628280-26-016491-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ADCT on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Switzerland |
| IPO year | 2020 |
| SEC CIK | 0001771910 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Switzerland |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $81.4M |
| Net income | -$142.6M |
| Operating income | -$121.5M |
| Net margin | -175.3% |
| Operating margin | -149.3% |
| Revenue growth | +14.9% |
| Cash | $261.3M |
| Total assets | $323.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $189.2M cash; operating cash flow -$25.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 127,667,695 (2026-08-03); 112,499,395 a year earlier. | Cover page 2026-08-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers AG, Lausanne, Switzerland | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $19.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $21.7M | -$25.3M | -$27.9M | $189.2M | $7.8M | $84.9M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $19.2M | -$16.6M | -$11.8M | $219.1M | $6.2M | $79.6M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $20.9M | -$33.0M | -$29.7M | $231.0M | $4.6M | $79.2M | 10-Q 2026-05-04 |
| Q4 2025 2025-12-31 | $23.1M | -$6.4M | -$31.1M | $261.3M | $3.0M | $81.4M | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | $16.4M | -$41.0M | -$29.6M | $234.7M | No debt tags | $75.2M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $18.8M | -$56.6M | -$24.1M | $264.6M | No debt tags | $77.2M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $23.0M | -$38.6M | -$56.3M | $194.7M | No debt tags | $75.8M | 10-Q 2026-05-04 |
| Q4 2024 2024-12-31 | $16.9M | -$30.7M | -$21.9M | $250.9M | $0 | $70.8M | 10-K 2026-03-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2026-11-10 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-04-20 |
Source: SEC EDGAR submissions feed, 442 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.2% |
| 1 month | -21.2% |
| 3 months | +27.6% |
| Year to date | -62.0% |
| 1 year | -66.9% |
| From 52-week high | -72.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BBOT | BridgeBio Oncology Therapeutics Inc. Common Stock | $1.98 | -7.48% | $158.9M |
| ZNTL | Zentalis Pharmaceuticals Inc. | $1.60 | -5.88% | $157.2M |
| ELDN | Eledon Pharmaceuticals Inc. | $1.97 | -6.86% | $166.4M |
| PRQR | ProQR Therapeutics N.V. | $1.18 | -16.31% | $166.5M |
| PYXS | Pyxis Oncology Inc. | $1.41 | -10.76% | $168.6M |
| ORMP | Oramed Pharmaceuticals Inc. | $3.90 | +5.12% | $169.6M |
| ANTX | AN2 Therapeutics Inc. | $4.47 | -1.76% | $169.6M |
| ABEO | Abeona Therapeutics Inc. | $2.60 | +7.44% | $148.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier